PRINCETON, NJ – 2024 年 4 月 16 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions. Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to … Continued
PRINCETON, N.J.— 2024 年 4 月 9 日– Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening … Continued
Provides Full Year 2024 Financial Guidance PRINCETON, N.J.— 2024 年 2 月 29 日– Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: “We are encouraged by our strong fourth quarter results, driven by improved execution across both software and services,” said William … Continued
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) — Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at … Continued
Certara和Applied Biomath联合建立生命科学行业最大的定量系统药理学（QSP）高级研究中心，有助于更快、更有效地开发药物。2023年12月14日，美国新泽西州普林斯顿 — Certara 公司（纳斯达克股票代码：CERT) today announced it has acquired Applied Biomath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and … Continued
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies Princeton, NJ – November 21st, 2023 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex … Continued
Reiterates Full Year 2023 Financial Guidance PRINCETON, N.J.— November 8, 2023– Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023. Third Quarter Highlights: “During the third quarter we saw customer demand stabilize across the Certara platform. We continue to see strong interest from … Continued
PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) — Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors … Continued
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines. PRINCETON, NJ – September 19th, 2023 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to regulatory agencies worldwide. Submissions include those to initiate clinical trials, such as Investigational New Drug (IND) or Clinical … Continued
PRINCETON, N.J., Aug. 29, 2023 — Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Live webcasts for each of the conferences will be available on Certara’s investor relations website athttps://ir.certara.com and will be available for replay for at least 90 days thereafter. … Continued
